• Abdullah Algaissi, Edrous Alamer, Mohammed Jeraiby, Abeer Alomaish, Omer Elrhima, Sultan Qumayi, Naaif A Qasir, Halima Areeshi, Asma Masmali, and Abdulaziz Alhazmi.
• From the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
• Saudi Med J. 2022 Jun 1; 43 (6): 567-571.

ObjectivesTo evaluate hematological parameters and thrombotic profiles of healthy individuals who received Pfizer-BioNTech (BNT162b2) vaccines in Saudi Arabia.MethodsHematological parameters and the incidence of anti-platelet factor-4 (anti/PF-4) antibodies were evaluated in 40 participants who were eligible for COVID-19 vaccination in Saudi Arabia (above 18 years old) at Jazan University Hospital. These parameters were assessed at 2 different timepoints; at day 0 (the day of receiving the first dose of Pfizer- BioNTech (BNT162b2) and prior to vaccination) and 14-21 days after receiving the vaccine.ResultsAmong the participants, 38 (80%) were men, while 12 (20%) were women, with a mean age of 27 years. A total of 15% of the participants reported previous infection with SARS-CoV-2 and 3 patients had a history of diabetes mellitus and hypertension. Hematological parameters results in those vaccines showed no significant changes between the 2 timepoints, such as, day 0 (just before receiving vaccination) and 14 to 21 days post vaccination. Further, anti/PF4 antibodies were negative for all participants following vaccination.ConclusionOur data showed that the incidence of hematological abnormalities or induction of anti/PF4 antibodies following Pfizer-BioNTech (BNT162b2) vaccination is not common, which is consistent with several previous reports. However, larger studies with more participants evaluated at different timepoints following vaccination are warranted to exclude potential transient hematological abnormalities.Copyright: © Saudi Medical Journal.

20 keywords...

hide…